Mirogab 5mg Tablet 10pcs

Neuropathic Pain (NeP) is a significant global health issue that causes considerable suffering and disability. It leads to substantial morbidity and adversely impacts the quality of life, particularly affecting sleep, mood, and overall functionality. The increasing prevalence of NeP necessitates the development of new treatments to better manage this condition and improve patient outcomes.

Mirogabalin Besylate (Tarlige)

Mirogabalin besylate (Tarlige) is a novel gabapentinoid therapy developed by Daiichi Sankyo. It has been approved in Japan for the treatment of postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (DPNP).

Mechanism of Action

Mirogabalin works by modulating pain through its interaction with the α2δ-1 subunit of voltage-gated calcium channels (VGCCs) on the dorsal root ganglion. This interaction results in:

• High Affinity and Prolonged Dissociation Rate: Mirogabalin has a unique high affinity for the α2δ-1 subunit and a prolonged dissociation rate, leading to more sustained analgesia compared to traditional gabapentinoids.
• Rapid Dissociation from α2δ-2 Subunit: This characteristic potentially reduces the incidence of central nervous system-specific adverse events (AEs), contributing to a superior safety profile.

Efficacy

Mirogabalin’s potent pain-modulating effect is attributed to its high affinity and prolonged action on VGCCs, providing sustained relief from neuropathic pain.

Adverse Events (AEs)

The most common adverse events associated with mirogabalin include:

• Dizziness: Approximately 8-16%
• Somnolence: Approximately 6-24%
• Headache: Approximately 6-14%

Other less common AEs include constipation, nausea, diarrhea, vomiting, edema, fatigue, and weight gain. These AEs are relatively lower in incidence compared to those seen with traditional gabapentinoids.

Postmarketing studies are necessary to further evaluate mirogabalin’s:

• Analgesic Durability: Long-term effectiveness in managing neuropathic pain.
• Efficacy in Combination Therapy: Effectiveness when used alongside other antineuropathic agents such as tricyclic antidepressants, duloxetine, and tramadol/tapentadol.

Mirogabalin besylate represents a promising advancement in the treatment of neuropathic pain, offering sustained analgesia with a potentially better safety profile. Continued research and postmarketing studies will help solidify its place in neuropathic pain management, providing clinicians with an effective option for improving patient quality of life.